Form 4: Illumina's Chief of Global Operations, Kevin Pegels, Reports Acquisition of Restricted Stock Units and Performance Shares

Kevin Pegels, Chief of Global Operations at Illumina, reports the acquisition of restricted stock units and performance shares based on company performance metrics.

Summary

• On March 5, 2025, Kevin Pegels, Chief of Global Operations at Illumina, reported acquiring 7,283 shares of common stock.
• These shares were acquired as restricted stock units, vesting in four equal installments on February 15 of 2026, 2027, 2028, and 2029, contingent upon continued service.
• Pegels also acquired 8,496 performance shares tied to Illumina's three-year average operating margin for fiscal years 2025-2027, vesting on January 2, 2028.
• The number of shares issued for these performance stock units will range from 0% to 250% of the specified amount, based on the company's actual performance relative to pre-defined objectives.
• Additionally, Pegels acquired 8,496 performance shares linked to Illumina's relative total shareholder return for the fiscal year ending January 2, 2028, also vesting on January 2, 2028.
• Similar to the operating margin-based shares, the number of shares issued for these performance stock units will range from 0% to 250% of the specified amount, based on the company's performance relative to pre-defined objectives.
• Following these transactions, Pegels directly owns 23,075 shares of Illumina common stock, 8,496 performance shares related to operating margin, and 8,496 performance shares related to shareholder return.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, aligning management interests with company performance. This is generally viewed positively, hence the score of 7.

Positives

• The grant of restricted stock units and performance shares aligns Kevin Pegels' interests with the long-term success of Illumina.
• The performance-based shares incentivize Pegels to drive improvements in both operating margin and shareholder return.

Risks

• The actual number of performance shares received will depend on Illumina's performance against pre-defined objectives, introducing uncertainty.
• The vesting of restricted stock units and performance shares is contingent upon Pegels' continued service with the company.

Future Outlook

The number of performance shares ultimately received by Kevin Pegels will depend on Illumina's performance against pre-defined objectives for operating margin and shareholder return over the specified periods.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain top talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Companies like Thermo Fisher Scientific and Danaher also utilize restricted stock units and performance-based equity awards to incentivize their executives.
• The specific metrics used for performance shares, such as operating margin and shareholder return, are common benchmarks for evaluating company performance in the life sciences industry.
• The vesting schedules and potential payout ranges (0% to 250%) are also within the typical range observed in similar companies.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to improve company performance.
• Employees may see the grants as a sign of confidence in the company's future prospects.

Key Dates